Zai Lab Limited stock is down -3.09% since 30 days ago. The next earnings date is Feb 28, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 42.86% of the previous 6 December’s closed higher than November. In the last 5 Unusual Options Trades, there were 3 PUTs, 2 CALLs. 100% of analysts rate it a buy.
|Date & Time||Expiration Date||Strike Price||Trade Type||Size||Open Interest|
|23 Oct 15:49||15 Dec, 2023||25.00||136|
|27 Oct 16:20||15 Dec, 2023||22.50||4|
|08 Nov 15:14||15 Dec, 2023||35.00||13|
|08 Nov 20:12||15 Mar, 2024||30.00||7|
|24 Nov 17:22||21 Jun, 2024||25.00||1|
Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. The company's commercial products include Zejula, a once-daily small-molecule poly polymerase 1/2 inhibitor; Optune, a device that delivers tumor treating fields; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia. It also develops Odronextamab, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer